Immune: Immune: Simvastatin addition to improve symptoms cognition, metabolic syndrome and movement disorders in patients with recent-onset psychotic disorder. A multi-center randomized, placebo-controlled, double-blind trial. [2015 – 2019 in uitvoering]

14 jul 2000

Location(s)

  • UMCU, UCP (UMCG), Lentis

Cooperation

  • UMCU, Lentis, GGZ Centraal, GGZ NHN, Arkin, Altrecht Antonius, Tergooi, GGZinGeest, Delta, Jeroen Bosch

Period
2015 – 2019

Finance
unknown

Finance by

  • The Stanley Medical Research Institute, ZonMw

Status
in uitvoering

Contact(s)
Mw. M. Bak
m.bak@umcg.nl

Abstract
There is evidence that inflammatory processes play a role in the pathophysiology of schizophrenia. Patients also tend to have an increased cardiovascular risk. The combination of well-established vascular protection and reduction of inflammation by simvastatin offers a highly attractive potential to further improve the treatment of schizophrenia.In patients who have been diagnosed with a psychotic disorder in the past three years we will investigate if daily treatment with 40 mg simvastatin in addition to antipsychotic treatment reduces psychotic symptoms, improves cognition, attenuates brain volume loss, and decreases the risk for metabolic syndrome as well for movement disorders, as compared to placebo.